Clicky

Cansino Biologics Inc.(6185)

Description: CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.


Keywords: Medicine Biotechnology Life Sciences Vaccines Vaccination Virology Shingles Meningitis Ebola Pertussis Preclinical Stage Products Tb Ebola Vaccine Book:Medications Polio D Tc P Booster Vaccine N. Meningitides Adult Vaccine Convidecia Pcv13i Recombinant Novel Coronavirus Disease Tdcp Adolescent

Home Page: www.cansinotech.com

401-420, Biomedical Park
Tianjin,
China
Phone: 400 922 2099


Officers

Name Title
Dr. Xuefeng Yu Ph.D. Co-Founder, Chairman, CEO & GM
Dr. Tao Zhu Ph.D. Co-Founder, Exec. Director, Deputy GM & Chief Scientific Officer
Dr. Dongxu Qiu MBA, Ph.D. Co-Founder, Exec. VP, Exec. Director & Deputy GM
Ms. Xi Luo Chief Financial Officer
Dr. Shou-Bai Chao Exec. Director, COO & Deputy GM
Mr. Chunlin Xin Sr. Director of New Technology Department
Mr. Yonghui Wu VP of Marketing
Ms. Jing Wang Chief Commercial Officer, Deputy GM & Exec. Director
Mr. Ming King Chiu FCIS, FCS Joint Company Sec.

Exchange: HK

Country: HK

Currency: Hong Kong Dollar (HK$)

Forward PE: 0
Trailing PE: 16.3341
Price-to-Book MRQ: 2.3774
Price-to-Sales TTM: 17.561
IPO Date:
Fiscal Year End: December
Full Time Employees: 1946
Back to stocks